SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07:
|
Submission of Matters to a Vote of Security Holders. |
At the 2017 annual meeting of stockholders of Sangamo
Therapeutics, Inc. (the Company) held on June5, 2017, the
following proposals were approved by the stockholders: (i)the
election of seven (7)nominees listed in the proxy statement to
serve on the Board of Directors of the Company, (ii)the
compensation of named executive officers of the Company as
disclosed in the proxy statement, on an advisory basis, (iii)the
frequency of every year to hold a stockholder vote to approve the
compensation of the Companys named executive officers, on an
advisory basis, and (iv)the ratification of appointment of Ernst
Young LLP as the Companys independent registered public
accounting firm for the fiscal year ending December31, 2017, each
by the votes set forth below:
Proposal 1: Election of Directors:
Each of the nominees for directors listed in the proxy statement
for the 2017 annual meeting of stockholders was elected by the
votes set forth in the table below:
|
Name of Director |
For | Against | Abstain | BrokerNon- Votes | ||||||||||||
|
H. Stewart Parker |
30,428,463 | 381,997 | 193,431 | 32,887,094 | ||||||||||||
|
Robert F. Carey |
30,246,759 | 530,366 | 226,766 | 32,887,094 | ||||||||||||
|
Stephen G. Dilly, M.B.B.S., Ph.D. |
30,596,046 | 219,009 | 188,836 | 32,887,094 | ||||||||||||
|
Alexander D. Macrae, M.B., Ch.B., Ph.D. |
30,306,285 | 539,070 | 158,536 | 32,887,094 | ||||||||||||
|
Steven J. Mento, Ph.D. |
30,414,117 | 403,438 | 186,336 | 32,887,094 | ||||||||||||
|
Saira Ramasastry |
30,475,031 | 310,507 | 218,353 | 32,887,094 | ||||||||||||
|
William R. Ringo |
26,415,660 | 4,425,045 | 163,186 | 32,887,094 |
Proposal 2: Approval, on an advisory basis, of the
compensation of the named executive officers as disclosed in the
proxy statement:
The compensation of the named executive officers as disclosed in
the proxy statement for the 2017 annual meeting of stockholders
was approved by the votes set forth in the table below:
|
For |
Against |
Abstain |
Broker Non-Votes |
|||
| 25,012,893 | 4,992,683 | 998,315 | 32,887,094 |
Proposal 3: Approval, on an advisory basis, as to whether the
advisory stockholder vote to approve the compensation of the
named executive officers should occur every year, once every two
years or once every three years:
|
1 Year |
2 Years |
3 Years |
Abstain |
Broker Non-Votes |
||||
| 27,354,749 | 188,724 | 3,009,846 | 450,572 | 32,887,094 |
In light of the stockholder vote on Proposal 3, the Company will
include an advisory stockholder vote on the compensation of the
named executive officers in its proxy materials once every year
until the next required vote on the frequency of stockholder
votes on the compensation of named executive officers.
Proposal 4: Ratification of Appointment of Independent
Registered Public Accounting Firm:
The appointment of Ernst Young LLP as the Companys independent
registered public accounting firm for the fiscal year ending
December31, 2017 was ratified by the votes set forth in the table
below:
|
For |
Against |
Abstain |
Broker Non-Votes |
|||
|
61,872,171 |
1,793,130 | 225,684 |
About SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO)
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has developed technologies available for gene-based therapies. Its product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Its zinc finger nuclease (ZFN) in vivo genome editing approach is being evaluated in Phase I/II clinical trials to treat hemophilia B and lysosomal storage disorders mucopolysaccharidosis (MPS) I and MPS II. It is also conducting a Phase I/II clinical trial to evaluate its adeno associated virus (AAV) complementary deoxyribonucleic acid (cDNA) human Factor 8 gene therapy approach, SB-525, to treat hemophilia A. It has investigational new drug application for SB-525. It is also developing ZFN-mediated genome editing-based therapies for blood disorders and cancer.